Religare Enterprises grants 13,195 ESOPs at ₹227.35 per share
Religare Enterprises Limited granted 13,195 stock options to employees under its 2019 ESOP scheme on August 12, 2026. The options vest in five equal annual installments with an exercise price of ₹227.35 per share. The grant complies with SEBI Listing Regulations and does not currently impact diluted EPS as no options have been exercised.
*this image is generated using AI for illustrative purposes only.
The Nomination and Remuneration Committee of Religare Enterprises approved the grant of 13,195 stock options to eligible employees under the company’s Employee Stock Option Plan 2019 during a meeting held on August 12, 2026. This equity incentive move aligns employee interests with shareholder value creation, as the options carry an exercise price of ₹227.35 per share and vest over a five-year period.
The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scheme itself conforms to the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, having received prior approval from both the Board of Directors and shareholders. Each stock option is convertible into one equity share with a face value of ₹10.
Key Terms of the Grant
The structural details of the option grant are outlined below:
| Parameter | Details |
|---|---|
| Total Options Granted | 13,195 |
| Exercise Price | ₹227.35 per share |
| Vesting Schedule | 5 equal annual installments (20% each) |
| First Vesting Date | Completion of one year from grant date |
| Maximum Tenor | 8 years from date of vesting |
Under the vesting schedule, 2,639 options will vest annually for five consecutive years, starting one year after the grant date. Employees must exercise their vested options no later than eight years from the respective vesting dates. As of the filing date, no options have been exercised, lapsed, or cancelled, and there have been no variations to the terms of the options.
Impact on Shareholder Metrics
Since the options remain unexercised, they do not currently impact the diluted earnings per share (EPS) or the total number of outstanding shares. The potential dilution will only materialize if and when employees exercise their rights to convert the options into equity shares. The fixed exercise price of ₹227.35 serves as the baseline cost for employees to acquire these shares, reflecting the valuation parameters set by the committee at the time of grant.
The company’s Group General Counsel & Group Chief Compliance Officer, Babu Rao P., certified the disclosure to the National Stock Exchange of India Ltd. and BSE Limited. The filing ensures transparency regarding the equity compensation structure and its adherence to regulatory frameworks governing share-based benefits in India.
Historical Stock Returns for Religare Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.56% | -8.21% | -12.19% | -6.92% | -7.50% | +56.29% |
How might the ₹227.35 exercise price influence employee retention rates if Religare Enterprises' stock price underperforms market benchmarks over the next five years?
What is the potential impact on diluted EPS and shareholder equity once the 13,195 options begin vesting and are subsequently exercised?
How does this specific ESOP grant compare to previous compensation structures in terms of aligning long-term management goals with shareholder value?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
